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Endometrial cancer 
Endometrial cancer (EC) is the most common gynecologic malignancy in developed 
countries. It is estimated that more than 52,000 new cases will be diagnosed in the 
United States during 2014 (1).   
EC is a type of cancer that begins in the uterus. The uterus is the hollow, pear-shaped 
pelvic organ in women where fetal development occurs. EC begins in the layer of cells 
that form the lining (endometrium) of the uterus (Figure 1). EC is sometimes called 
uterine cancer. Other types of cancer can form in the uterus, including uterine sarcoma, 
but they are much less common than endometrial malignancies. EC is often detected at 
an early stage because it frequently produces abnormal vaginal bleeding, which prompts 
women to see their doctors. If EC is discovered early, removing the uterus surgically 
often cures EC. Hysterectomy plus salpingo-oophorectomy is the cornerstone for 
treatment of EC, but the use of lymphadenectomy, especially in early-stage disease, is a 
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Role of Surgical Staging 
 Despite the high incidence of EC, many features of its management remain 
unresolved. The main controversial topic in EC treatment concerns the therapeutic role 
of lymphadenectomy (3). Definitions of the adequacy and extent of lymphadenectomy 
have not been fully established. 
         In 1988, the International Federation of Gynecology and Obstetrics (FIGO) 
introduced the concept of surgical staging of EC (4), and in 2005, the American College 
of Obstetricians and Gynecologists (ACOG) recommended surgical staging as an 
important part of EC management. The ACOG committee suggested that “adjuvant 
therapy” should be limited to patients with positive nodes, while “the use of adjuvant 
radiation therapy in women with disease limited to the uterus based on systematic 
surgical staging is controversial” (5). Theoretically, the removal of lymph nodes has 
several potential advantages. Complete surgical staging may allow the identification of 
patients with documented lymphatic dissemination, thus targeting postoperative 
treatment and potentially reducing the morbidity related to unnecessary radiation 
therapy. Moreover, lymph node dissection may eradicate metastatic lymphatic disease.  
         The major criticisms of lymphadenectomy are based on the results of 2 
independent randomized trials that evaluated the role of pelvic and limited para-aortic 
lymph node dissection in early-stage EC (6,7). Overall, a total of 1,922 patients were 
randomly assigned to evaluate whether the addition of pelvic (and para-aortic, in 
selected cases) lymphadenectomy to standard hysterectomy with bilateral salpingo-
oophorectomy may improve survival outcomes. The cumulative results of these studies 
reported that lymphadenectomy did not improve disease-free survival (pooled hazard 
ratio [HR], 1.23; 95% confidence interval [CI], 0.96-1.58) and overall survival (pooled 
HR, 1.07; 95% CI, 0.81-1.43) (6,7). 
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         These findings should be interpreted with caution, however, because of several 
pitfalls in the study design of both trials. First, they included a large proportion of low-
risk women, which diluted the possible therapeutic effects of lymphadenectomy. Given 
the low rate of lymphatic spread in the early stage of disease (9%-13%), it is not 
surprising that the 2 trials failed to find any therapeutic role for pelvic 
lymphadenectomy in the low-risk population. Second, no clear indication was given for 
postoperative adjuvant therapy. One of the main goals of lymphadenectomy is to tailor 
adjuvant treatment to decrease radiation-related morbidity in patients with negative 
nodes. However, the adjuvant therapy administration rate was similar in both study 
arms; this result obviously influenced postoperative outcomes. Third, neither trial 
evaluated appropriately the role of para-aortic lymphadenectomy. In patients with 
lymphatic spread, para-aortic node involvement occurs in 60% of patients with 
endometrioid EC and 70% of those with nonendometrioid EC (8). Therefore, the 
performance of pelvic lymphadenectomy alone represents an incomplete surgical effort 
because of the partial removal of metastatic nodes.  
         Additionally, in the ASTEC trial (7), the number of pelvic nodes yielded was low 
in many of the patients. The median number of pelvic nodes harvested was 12 (range, 1-
59); moreover, in the lymphadenectomy arm, 241 women (35%) had 9 or fewer nodes 
and 72 women (12%) had 4 or fewer nodes.  
         Recently, in response to the current evidence that pelvic lymphadenectomy alone 
did not provide any significant benefit on EC, Todo et al (9) designed a retrospective 
cohort analysis (the SEPAL study) aimed at assessing the role of para-aortic 
lymphadenectomy. The authors compared outcomes of patients undergoing systematic 
pelvic lymphadenectomy or combined pelvic and para-aortic lymphadenectomy in 
intermediate- and high-risk EC patients. The SEPAL study showed that high-risk 
patients who had pelvic and para-aortic lymph node dissection experienced a longer 
overall survival than patients who had pelvic lymphadenectomy alone (HR, 0.53; 95% 
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CI, 0.38-0.76; P<.001). Interestingly, in accordance with our previous comments, the 
authors found that survival was not influenced by the performance of para-aortic 
lymphadenectomy in the low-risk group (grade 1 and 2 endometrioid tumor limited to 
the inner half of the myometrium, without lymphovascular space invasion), while it was 
an independent prognostic factor in intermediate-risk EC patients (grade 1 and 2 tumor 
limited to the inner half of the myometrium with lymphovascular space invasion, grade 
3 and/or nonendometrioid stage IA and IB tumor, stage IC and II) and high-risk EC 
patients (stage III and IV) (P<.001) (9). However, only 8% of patients in the SEPAL 
trial had nonendometrioid EC (13.5% of the intermediate- and high-risk group). 
Therefore, results of the SEPAL trial may not be fully applicable to patients with 
nonendometrioid EC. Also, the median age of patients in the SEPAL trial was relatively 
young (56 years), and those results may not be applicable to elderly patients (9). 
Clinical Considerations 
         In light of the current evidence, it is not possible to draft definitive conclusions 
regarding the role of lymphadenectomy in EC patients. In this article, we will address 
the most important questions regarding the role of lymphadenectomy in EC:  
1.    Which is the population at risk of lymphatic spread?  
2.    How can we select patients at risk of lymphatic spread?  
3.    Which are the patterns of para-aortic lymphatic spread?  
4.    What is the role of sentinel lymph node (SLN) mapping?  
5.    How does lymphadenectomy impact morbidity, quality of life (QOL), and 
costs?  
6.    If lymph node metastases are identified, do we have adequate treatment?  
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7.    How can we design a study to test the diagnostic and therapeutic role of 
lymphadenectomy?  
1. Which Is the Population at Risk of Lymphatic Spread? 
         According to a risk stratification system in use at Mayo Clinic, Rochester, MN  
(Table 1), low-risk patients can be adequately treated with removal of the uterus and 
adnexa alone, without significantly compromising survival. In this subgroup, 
lymphadenectomy carries only potential adjunctive morbidity (10,11). In fact, we 
previously demonstrated that tumor diameter significantly influences the risk of lymph 
node dissemination. In an analysis of more than 300 endometrioid EC patients with 
FIGO grade 1 or 2 and myometrial invasion limited at the inner half, we found that no 
patients with tumor diameter of 2 cm or less had positive lymph nodes or lymph node 
recurrences or died of disease (11). This finding has been recently prospectively 
validated by our group (10) and others (12,13). 
         Based on the surgical protocol currently in use at Mayo Clinic, all patients with 
primary epithelial EC undergo hysterectomy with or without bilateral salpingo-
oophorectomy. The need to perform lymphadenectomy is based on the tumor 
characteristics (histologic type, FIGO grade, tumor diameter, and depth of myometrial 
invasion) determined at frozen-section analysis. Systematic pelvic and para-aortic 
lymphadenectomy is performed when patients have myometrial invasion greater than 
50%, nonendometrioid histology, or both. If patients do not match these characteristics, 
the choice to perform pelvic node dissection (with para-aortic lymphadenectomy only in 
those patients with documented pelvic lymph node metastases) is based on cervical 
involvement, FIGO grade, and tumor diameter (Figures 1 and 2). Para-aortic 
lymphadenectomy is therefore limited to patients with at least one of the following: 1) 
positive pelvic nodes (assessed at frozen section); 2) type 2 EC; or 3) deep myometrial 
invasion (>50%) (Figure 1) (14). In fact, we have recently observed that isolated para-
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aortic dissemination (in the absence of pelvic lymph node involvement) is generally 
very uncommon (£5%), with the exception of patients with endometrioid grade 2 or 3 
cancer and myometrial invasion greater than 50% (15). Also, para-aortic metastases are 
uncommon in patients with endometrioid grade 3 cancer with early myometrial invasion 
(£50%) (14). 
         When type II EC omentectomy is performed (Figure 1), random peritoneal 
biopsies, in the absence of macroscopic visible disease, are of limited diagnostic benefit 
(16). 
         Interestingly, in a large analysis among high-risk and ultra-high-risk (grade 3 
endometrioid, serous, and clear cell) uterine cancers, we showed that lymphadenectomy 
as well as extensive surgery did not provide survival advantages in patients with 
advanced-stage disease (17). 
         In light of these findings, patients with a preoperative diagnosis of FIGO grade 1 
or 2 endometrioid EC confined to the endometrium or with myometrial invasion less 
than 50% and tumor diameter of 2 cm or less do not undergo lymph node dissection at 
our institution. Moreover, from a practical standpoint, lymphadenectomy may be 
omitted also in ultra-high-risk patients with stage IV disease (Figure 2).  
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Figure 2. Algorithm for surgical management of endometrial cancer at our institution. 
In the case of type 2 endometrial cancer, omentectomy is required. No 
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2. How Can We Select Patients at Risk of Lymphatic Spread? 
         A scoring system based on preoperative and operative parameters should be used 
to tailor surgery and reduce the rate of unnecessary lymphadenectomy. Several models 
have been described (18-24). Decision making at Mayo Clinic is traditionally based on 
4 variables during intraoperative frozen-section analysis: primary tumor diameter, FIGO 
grade, histologic type, and depth of myometrial invasion. An investigation by our 
group, aimed at determining the reliability of frozen-section analysis, suggested a high 
rate of clinical accordance (98.7%), with definitive pathologic findings (permanent 
paraffin sections). Among 784 patients included, 10 women (1.3%) had a potential 
change in operation plan due to deviation in pathologic results from frozen-section to 
permanent-paraffin analysis. This included changes in histologic subtypes (n=6, 0.7%), 
FIGO grade (n=1, 0.12%), and myometrial invasion (n=3, 0.38%) (18). Although 
different studies from other institutions report a similarly high accuracy rate of 
intraoperative frozen section (25,26), a survey of the Society of Gynecologic 
Oncologists revealed that only 31% of gynecologic surgeons use frozen section in their 
decision making for EC management (27). For this reason, we recently showed that, in 
the absence of an accurate frozen section, preoperative biopsy (which is consistently 
available) and intraoperative tumor diameter (easily measured on fresh tissue and 
unchanged on final pathology) may reliably predict lymph node tumor spread. We 
observed that low-risk women (patients with preoperative diagnosis of grade 1 or 2, 
endometrioid EC and tumor diameter £2.0 cm) have less than 1% risk of lymphatic 
spread, while patients with tumor diameter greater than 2.0 cm or with preoperative 
diagnosis of endometrioid grade 3 or nonendometrioid EC had a substantial risk of 
lymphatic involvement greater than 10% (Figure 3) (19).  
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Figure 3: Risk of lymph node metastasis and lymph node recurrence according to 
preoperative and operative findings. LN indicates lymph node; mts, metastases; TD, 
tumor diameter. (Data from AlHilli et al [19].) 
         Other authors have used preoperative imaging and serum markers, suggesting that 
tumor volume (measured with magnetic resonance imaging), positron-emission 
tomographic scan findings (28), and preoperative cancer antigen 125 or human 
epididymis protein 4 levels may be useful in tailoring the indications for 
lymphadenectomy (20,21,29). 
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         Our experience suggests that frozen-section analysis may represent a safe and 
effective method to direct the operative plan in selected medical centers. However, if 
frozen-section analysis is not available or if it is not reliable, findings of preoperative 
endometrial sampling associated with intraoperative tumor size, imaging studies, and 
serum markers are alternative methods to identify patients who may benefit from 
comprehensive surgical staging.  
3. Which Are the Patterns of Para-aortic Lymphatic Spread? 
         Traditional imaging, node palpation through the peritoneum, and node sampling 
are inaccurate in predicting lymph node positivity (5). In 2005, ACOG recommended 
that “retroperitoneal lymph node assessment is a critical component of surgical staging” 
because it “is prognostic and facilitates targeted therapy to maximize survival and to 
minimize the effect of undertreatment and potential morbidity associated with 
overtreatment” (5). Nevertheless, in clinical practice a high variation of procedures 
reflects the lack of standardization of lymphadenectomy: techniques vary from elective 
omission to simple lymph node sampling, to systematic pelvic lymphadenectomy with 
or without para-aortic lymphadenectomy.  
         One investigation at Mayo Clinic illustrated the prevalence and site of pelvic and 
para-aortic lymphatic metastases. We reported that, among patients with lymphatic 
spread, 84% and 62% had pelvic and para-aortic node metastases, respectively. In 
particular, 46%, 38%, and 16% had involvement of both pelvic and aortic nodes, pelvic 
nodes only, and aortic nodes only, respectively (8).  
         Para-aortic lymph nodes can be classified based on their location above and below 
the inferior mesenteric artery (IMA). At Mayo Clinic, we evaluated para-aortic 
metastatic site frequency relative to the IMA and found that aortic nodes above the IMA 
were involved in 77% of cases (8,30). Fotopoulou and coworkers (31) corroborated 
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these results; they reported that metastatic disease above the IMA was recorded in 54% 
and 70% patients with stage IIIC and IIIC2 EC, respectively. Recently, a prospective 
study by our department suggested that, considering patients with aortic node 
involvement, high para-aortic lymph node metastases were detected in 88% of them, 
with no discernible difference between endometrioid (89%) and nonendometrioid (88%) 
histologic subtypes. Interestingly, 35% of patients with high para-aortic lymph node 
metastases had negative nodes below the IMA (39% endometrioid; 31% 
nonendometrioid). Furthermore, in the rare cases with para-aortic lymph node 
metastases and negative pelvic nodes, cancer dissemination is most commonly confined 
to the high para-aortic area (67%) (15).  
         Also, patients with pelvic node metastases may have occult aortic node 
involvement, with a rate of para-aortic dissemination higher than commonly reported. 
Todo et al (32) investigated the occurrence of occult metastases (ie, micrometastases 
and isolated tumor cells) in the para-aortic area in patients with stage IIIC1 EC who 
underwent pelvic and para-aortic lymphadenectomy. Ultra-staging was performed by 
multiple slicing, staining, and microscopic inspection of the specimens. The authors 
found that 73% of these patients had occult aortic node involvement. Although the role 
of micrometastases is not fully understood, the presence of microscopic occult disease 
in the para-aortic area should be considered even in stage IIIC1 EC or in those patients 
with documented pelvic lymph node invasion and no known information regarding the 
para-aortic area.  
         These findings indicate that para-aortic lymph node invasion is very common 
when pelvic lymph node metastases are demonstrated. Also, in the majority of patients 
with para-aortic lymph node invasion, the area above the IMA is involved. Table 2 
shows the overall risk of para-aortic and high para-aortic lymph node metastasis in EC.  
4. What Is the Role of SLN Mapping? 
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         SLN mapping is an accepted way to assess lymphatic spread in several solid 
tumors (ie, breast cancer, vulvar cancer, and melanoma) and is gaining ground in 
cervical cancer and EC (33-35). SLN biopsy can be considered a compromise between 
comprehensive surgical staging and the complete omission of lymphadenectomy. In an 
ideal world, SLN mapping should be as good as a systematic lymphadenectomy in the 
identification of patients with lymph node dissemination, while reducing the morbidity 
associated with an extensive surgical procedure.  
         Although the complexity of uterine lymphatic drainage may discourage use of this 
procedure, the estimated accuracy rate is, in general, reasonably good (36-39). The 
prospective multi-institutional SENTI-ENDO study suggested that in stage I and II EC 
patients, SLN biopsy has a sensitivity of 84% (40). Moreover, ultra-staging of the SLN 
may be even more sensitive than a full lymphadenectomy, with lymph nodes evaluated 
by conventional pathology (35,41). However, we still do not know the clinical 
importance of isolated tumor cells discovered in a lymph node that is negative by 
traditional histologic analysis. Recently, a paper from the Memorial Sloan-Kettering 
Cancer Center, describing one of the largest prospective single-institution cohorts, 
showed that applying an SLN mapping algorithm may be a safe and effective alternative 
to systematic lymphadenectomy (38). The study pointed out that satisfactory SLN 
mapping requires adherence to a surgical algorithm and the removal of any “suspicious 
node” (38). However, the definition of a suspicious node was unclear. Also, 
identification of suspicious lymph nodes without fully opening the retroperitoneal 
spaces and without palpation (not possible with the minimally invasive approach) is 
limited and unreliable. 
         Like every effort aimed at decreasing the amount of surgery and the morbidity of 
EC treatment, we look at the experimental results on the use of SLN sampling with 
great interest. Ideally, SLN biopsy could be an effective alternative to systematic 
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lymphadenectomy. However, available data are still insufficient to define its role in 
clinical practice.  
5. How Does Lymphadenectomy Impact Morbidity, QOL, and Costs?  
         Patients undergoing systematic pelvic and para-aortic lymphadenectomy 
experience longer operative times and are exposed to greater risk of intraoperative and 
postoperative complications than patients who have hysterectomy and bilateral 
salpingo-oophorectomy alone (6). While some investigations showed that lymph node 
dissection did not significantly influence complication rates among EC patients (42,43), 
at Mayo Clinic, we observed that retroperitoneal staging, including para-aortic 
lymphadenectomy, increases morbidity in patients with EC (44). Similarly, results from 
the ASTEC trial and the Italian collaborative trial indicated that women who underwent 
lymphadenectomy had a significantly higher risk of surgically related morbidity and 
lymphatic complications than those who had hysterectomy plus bilateral salpingo-
oophorectomy alone (relative risk [RR], 3.72; 95% CI, 1.04-13.27, and RR, 8.39; 95% 
CI, 4.06-17.33, for risk of surgical and lymphatic complications, respectively) (6,7,45). 
However, it is important to note that the introduction of minimally invasive lymph node 
dissection may have reduced the complication rate of lymphadenectomy (46-48). 
         The impact of lymphadenectomy on long-term QOL in EC patients is not clear. 
Recently, a Dutch population-based analysis (49) evaluated the health-related QOL and 
symptoms following pelvic lymphadenectomy and radiation therapy (alone or in 
combination) vs no adjuvant therapy in patients with FIGO stage I and II EC. 
Lymphedema, gastrointestinal tract symptoms, diarrhea, back and pelvic pain, and 
muscular joint pain were the most commonly reported symptoms. The authors showed 
that, despite different symptom patterns, in patients who had pelvic lymphadenectomy 
(eg, lymphedema), radiotherapy (eg, diarrhea), or both, no clinical differences in overall 
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QOL were observed compared with women not receiving adjuvant therapy, 
lymphadenectomy, or both (49). 
         At Mayo Clinic, we analyzed the related surgical costs of lymphadenectomy in 
our low-risk EC population and reported that lymphadenectomy increased the median 
30-day cost of care by about $4,500 per patient (10).  
         In conclusion, patients undergoing lymphadenectomy experience longer operative 
times and higher complication rates than patients who have hysterectomy plus 
adnexectomy alone. Also, the overall cost of surgical care is higher. The influence of 
lymphadenectomy on long-term QOL is less clear. For the above reasons, it is important 
to limit the performance and the extent of lymphadenectomy to patients who may 
potentially benefit from it. 
6. When Lymph Node Metastases Are Identified, Is Adequate Treatment Available? 
         Although lymphadenectomy is aimed at documenting the presence of lymphatic 
metastases, there is still no consensus about the best adjuvant approach in EC patients 
with positive lymph nodes. The Gynecologic Oncology Group 122 trial (50) suggested 
that chemotherapy (doxorubicin and cisplatin) provides better survival than 
radiotherapy (whole abdominal irradiation) in stage III or IV and with 2 cm or less of 
residual disease. However, chemotherapy decreased the distant recurrence rate (from 
19% to 10%) at the cost of a higher pelvic recurrence rate (from 13% to 18%). 
Interestingly, the authors reported that chemotherapy was not significantly better than 
abdominal radiation in patients with nonendometrioid tumors (50). Similarly, the results 
of 2 randomized studies (NGSO/ERTC and MaNGO ILIADE–III), including high-risk 
EC patients (stage I to III), indicated that the addition of adjuvant chemotherapy to 
radiation improved disease-free survival overall, especially in the subgroup with grade 1 
and 2 endometrioid EC. Chemotherapy was less likely to be beneficial in patients with 
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endometrioid grade 3 and type 2 EC (51). In agreement with the above results, we 
recently demonstrated that chemotherapy did not significantly impact prognosis in stage 
III patients with high-risk histology (endometrioid grade 3 and type 2 EC) (17). 
Although in our study radiotherapy (with or without chemotherapy) independently 
influenced survival in patients with stage III poorly differentiated cancer, the treatment 
failure rates remained extremely high, with a 67% recurrence rate at 3 years in patients 
with stage III and lymphovascular invasion (17).  
         Similarly, Sutton et al (52), in another Gynecologic Oncology Group study, 
reported that patients with stage III and IV high-risk histology (serous and clear cell) 
experienced 3-year recurrence-free and overall survival of 27% and 35%, respectively, 
when treated with whole abdominal radiotherapy.  
         Owing to the fact that radiotherapy seems to provide adequate locoregional 
protection of the targeted tissues but not systemic control, several authors suggested that 
combining radiotherapy and chemotherapy may guarantee better locoregional and 
systemic protection (53,54). Alvarez Secord et al (55), in a multi-institutional series of 
265 stage IIIC ECs (type 1 and type 2), reported that patients undergoing chemotherapy 
alone had a 2.2- and 4.0-fold increased risk of recurrence and death than patients who 
had chemotherapy plus radiotherapy. In contrast, there was no difference in survival 
between patients undergoing radiotherapy alone vs chemotherapy plus radiotherapy. 
Interestingly, the authors showed that among patients undergoing the combined 
regimen, overall survival for a “sandwich” regimen of chemotherapy plus radiotherapy 
plus chemotherapy was 98% vs 90% for radiotherapy plus chemotherapy and 82% for 
chemotherapy plus radiotherapy. However, no difference in disease-free survival was 
recorded among these 3 combination regimens (55).  
         In conclusion, in stage IIIC EC, the therapeutic role of chemotherapy remains 
unproven, especially in type II and more aggressive endometrioid tumor (grade 3) (56). 
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Lymphadenectomy, like radiotherapy, is a locoregional treatment and likely has limited 
ability to prevent distant recurrences outside the surgical field, which in turn can be 
prevented only by an effective systemic treatment. It has been suggested that systemic 
cytotoxic chemotherapy may be more effective in advanced endometrioid grade 1 and 2 
EC and less effective in advanced poorly differentiated EC (17,46,51). For this reason, 
aggressive locoregional treatment (systematic lymphadenectomy and external 
radiotherapy) is more likely to improve the overall patient prognosis in tumors that are 
responsive to systemic adjuvant therapy.  
7. How Can We Design a Study to Test the Diagnostic and Therapeutic Role of 
Lymphadenectomy? 
         While the role of lymphadenectomy in the identification of patients with 
lymphatic dissemination is well established, its role in patient selection for targeting 
postoperative treatment, and therefore decreasing postoperative morbidity and 
improving QOL, is less clear. Similarly, the available data do not allow us to draw 
definitive conclusions on the therapeutic value of lymphadenectomy in EC patients. We 
believe that a trial aimed at demonstrating a therapeutic benefit of lymphadenectomy 
should focus on patients at significant risk (>15%) of lymph node dissemination (57). 
Two main questions should be addressed in the trial: 1) Is lymphadenectomy 
therapeutic or mainly diagnostic for directing postoperative adjuvant treatment? 2) Is 
lymphadenectomy increasing or decreasing the cumulative treatment-related (surgery 
with or without adjuvant therapy) morbidity, costs, and QOL? Although it is intuitive 
that a prospective, randomized controlled trial will best answer these questions, a well-
designed prospective cohort study is potentially more feasible and more likely to 
provide a definitive answer (58).  
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 The diagnostic role of lymphadenectomy in documenting areas of lymphatic 
dissemination is well recognized in EC. The identification of sites of tumor 
dissemination allows patient selection and targeting of postoperative treatment.  
         Based on our data on patterns of lymphatic dissemination in EC, we recently 
reported that isolated para-aortic dissemination (with negative pelvic nodes) is rare 
(usually <5%), with the exception of patients with deeply invasive endometrioid grade 2 
and 3 cancer, in whom this percentage is higher than 10% (15). For this reason, from a 
purely diagnostic perspective (ie, if lymphadenectomy is aimed only at identifying those 
patients with extrauterine disease), pelvic lymphadenectomy is usually sufficient (with 
the above exceptions, which include only 6% of the overall EC population [14]). 
However, if lymphadenectomy is therapeutic, as suggested by the SEPAL trial, the 
para-aortic area needs to be targeted by surgery, radiation, or both in most (if not all) 
patients with documented lymphatic dissemination in the pelvis (9,32). In these cases, 
we need also to be aware that para-aortic disease is usually present in the anatomic area 
above the IMA (15). 
         After many decades of debate, there are still not convincing data demonstrating a 
therapeutic role of lymphadenectomy in EC. Why is that? First, lymphadenectomy, like 
radiotherapy, is a locoregional treatment. For this reason, if lymphadenectomy is 
therapeutic, it is more likely to improve locoregional control and less likely to affect 
systemic disease. However, as overall patient survival is mainly driven by the presence 
of occult systemic disease, in the absence of an efficacious adjuvant systemic treatment, 
it is unlikely that lymphadenectomy will demonstrate any survival benefits (17). We are 
therefore in a difficult situation. Patients with poorly differentiated EC (grade 3 or type 
II) are more likely to present with occult lymphatic dissemination (15), but are also 
more likely to die of systemic disease (17). But patients with endometrioid grade 1 and 
2 cancer are less likely to die of systemic disease and more likely to respond to systemic 
treatment (51) and to be cured at the time of lymphatic recurrence (14). However, in 
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these patients, lymphatic dissemination is rare (14,15) (Figure 4), making it very 
difficult to demonstrate a therapeutic role of lymphadenectomy. Perhaps use of SLN 
mapping will be helpful for adequate patient selection in patients with low-risk tumor 
(38-41). The continuing debate about the role of lymphadenectomy will probably end 
only when molecularly guided imaging or new biologic therapy becomes available to 
identify and treat systemic metastatic disease.  
 
 
	   22	  
Figure 4: Risk of lymph node metastasis. Para-aortic lymph node metastases may be 
associated with lymphovascular space invasion. EC indicates endometrial cancer; LN, 
lymph node; MI, myometrial invasion; mts, metastases; PA, para-aortic; PL, pelvic. 
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Table 1. Endometrial Cancer Risk Stratification 
Low	  risk	  	  
	  	  	  	  	  	  Endometrioid,	  grade	  1	  and	  2,	  MI	  <	  50%,	  PTD	  ≤	  2	  cm	  
	  	  	  	  	  	  Endometrioid,	  MI	  0%,	  any	  grade	  or	  PTD	  
Low-­‐intermediate	  risk	  	  
	  	  	  	  	  	  Endometrioid,	  grade	  1	  and	  2,	  MI	  <	  50%,	  PTD	  >	  2	  cm	  (or	  unknown)	  
High-­‐intermediate	  risk	  
	  	  	  	  	  	  Endometrioid,	  grade	  1	  and	  2,	  50%	  <	  MI	  ≤	  66%	  
	  	  	  	  	  	  Endometrioid,	  grade	  3,	  MI	  <	  50%	  
High	  risk	  	  
	  	  	  	  	  	  Nonendometrioid	  
	  	  	  	  	  	  Endometrioid,	  grade	  1	  and	  2,	  MI	  >	  66%	  
	  	  	  	  	  	  Endometrioid,	  grade	  3,	  MI	  >	  50%	  
	  	  	  	  	  	  Adnexal	  metastasis	  
Ultra-­‐high	  risk	  (IP	  and	  EA	  spread)	  
	  	  	  	  	  	  Grade	  3	  EC,	  USC,	  and	  CCC	  subcohorts	  
	  	  
Abbreviations: CCC, clear cell carcinoma; EA, extra-abdominal; EC, endometrial cancer; IP, intra-peritoneal; MI, myometrial 
invasion; PTD, primary tumor diameter; USC, uterine serous cell carcinoma. 
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Table 2. Prevalence of Node Metastases in EC “At Risk” for Lymphatic Spread 
	   
Type of EC	  
	   
+PL Nodes, %	  
	   
+PA Nodes, %	  
	  
–PL Nodes With +PA Nodes, % 
Endometrioid	   	  	   	  	   	   
G1, MI =<50%a 3.8 0.8 0 
G1, MI >50% 15.2 9.4 0 
G2, MI ≤50%a 7.3 5.3 1.4 
G2, MI >50% 17.1 20.5 12.5 
G3, MI =<50% 6.9 0 0 
G3, MI >50% 35.3 25.0 27.3 
Nonendometrioid 19.5 13.1 3.4 
Abbreviations: –, negative; +, positive; EC, endometrial cancer; G, grade; MI, myometrial invasion; PA, para-aortic; PL, pelvic.  
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Robotic Surgery  
The da Vinci Surgical System is a sophisticated robotic platform designed to 
expand the surgeon’s capabilities and offer a state-of-the-art minimally invasive option 
for major surgery. The da Vinci Surgical System is a sophisticated robotic platform 
designed to expand the surgeon’s capabilities and offer a state-of-the-art minimally 
invasive option for major surgery. With the da Vinci Surgical System, surgeons operate 
through just a few small incisions. The da Vinci System features a magnified 3D high-
definition vision system and tiny wristed instruments that bend and rotate far greater 
than the human wrist. As a result, da Vinci enables your surgeon to operate with 
enhanced vision, precision, dexterity and control. 
Minimally invasive da Vinci uses the latest in surgical and robotics technologies. 
da Vinci is beneficial for performing routine and complex surgery. Your surgeon is 
100% in control of the da Vinci System, which translates his or her hand movements 
into smaller, more precise movements of tiny instruments inside your body. da Vinci – 
taking surgery beyond the limits of the human hand. Surgery is the mainstay of 
treatment for EC patients. Interestingly, in the last decade the EC surgical approach has 
been dramatically modified (59). Accumulating evidence supports that minimally 
invasive surgery upholds oncologic effectiveness of open surgery, minimizing peri-
operative morbidity (60-66). However, the diffusion of minimally invasive surgery 
evolved slower than expected (66). In fact, complex laparoscopic procedures require 
specialized technical skills (59-60). More recently, robotic-assisted technology has been 
developed in order to overcome limitations of conventional laparoscopic surgery. 
Robotic-assisted surgery provides better control of instrumentations, precision “scaling” 
of movements and three-dimensional vision, thus offering technical advantages to the 
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surgeons and increasing the rate of procedures performed via minimally invasive 
surgery (64-66).  
However, costs related to robotic-assisted surgery are a source of ongoing 
concerns (67,68). In fact, the main barrier to the diffusion of robotic-assisted technology 
is represented by its acquisition and instrumentation cost. Recently, several publications 
assessed the cost-effectiveness of robotic-assisted surgery in comparison to other 
surgical approaches for EC treatment (67-70). However, these studies did not adjust 
results based on confounding factors (related to patient-, disease- and surgical-
characteristics), thus limiting the interpretation of retrospective data comparisons. 
Additionally, investigations did not always take into account the increased costs of 
robotic-assisted surgery during its implementation phase and compared the new and still 
evolving robotic approach with other consolidated techniques.  
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Aim of the Study: 
In the present invesigation, we sought to evaluate the impact of the introduction 
of robotic-assisted surgery for EC on treatment-related morbidity and costs of surgical 
staging. We compared robotic-assisted to standard (open abdominal) staging surgery, 
thus auditing the experience of a high-volume institution. In addition, we evaluated how 
outcomes in robotic-assisted surgery improved with time and increasing expertise. 
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Methods of the study: 
The Mayo Clinic Institutional Review Board (IRB) approved the present study.  
All consecutive patients undergoing surgery for newly diagnosed EC at Mayo Clinic 
(Rochester MN, USA) during 01/02/2007 to 11/30/2012 were considered. In 
compliance with the Minnesota Statute for Use of Medical Information in Research, 
only the medical records for patients who consented to the use of their medical records 
were retrospectively reviewed.  
Inclusion criteria were: (a) primary treatment for epithelial EC; (b) the execution 
of surgical staging (including hysterectomy plus lymphadenectomy); (c) staging 
performed via robotic-assisted or open surgery; (d) non-stage IV disease. A small 
percentage of patients underwent vaginal and laparoscopic hysterectomy and surgical 
staging (Figure 5). They were excluded from the main analyses in the present study, and 
they will be analyzed separately in a different study (manuscript in preparation). 
Surgical procedures were performed according to Mayo Clinic’s surgical 
guidelines during the time period of the study. Details of the algorithm in use at Mayo 
Clinic are reported elsewhere (2). The open abdominal approach was the standard of 
care until 2006, with few exceptions (59,60). In 2007, we started a gradual 
implementation of the use of robotic-assisted surgery (59,60). Detailed descriptions of 
our surgical techniques and clinical protocols regarding perioperative patients’ 
management are reported elsewhere (2,71-73). During the study period there were no 
significant differences in the clinical pathway for women undergoing surgery for EC.  
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 Figure 5: Study design 
 
Demographic-, disease- and treatment-specific characteristics of patients were 
abstracted from the medical records. Data included general demographic characteristics, 
obstetrical, past medical (comorbidity conditions were classified by the Charlson 
comorbidity index (74)) and surgical histories, surgical results (operative time, blood 
loss, blood transfusion, uterine weight, as well as intraoperative and postoperative 
complications), length of stay, date of last-follow-up, and vital status (74,75). Operative 
times were recorded from the first skin incision to the last suture (skin to skin); for 
robotic-assisted procedures, operative times also included robot-docking time. Data on 
blood loss were extracted from surgical records, as estimated by the surgeon during the 
procedure. Hospital stay was calculated from the admittance date. Intraoperative 
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complications included any unintentional opening or damage to any organs or 
structures. We classified conversions as either conversions needed for completing 
staging procedures (mostly due to the inability to perform a high para-aortic 
lymphadenectomy via a robotic-assisted trans-peritoneal approach in obese patients) or 
conversions needed to manage intra-operative surgical complications or technical 
difficulties. The patient’s surgical modality was considered based on the intent to treat 
principle; hence, patients who had a conversion from a robotic-assisted to open 
approach were included in the robotic-assisted group. Postoperative complications were 
included if they occurred within 30 days after surgery. Only data about grade 2 or 
higher postoperative complications (according to the Accordion Severity Classification 
(76) were collected. 
Cost data for patients included in the study were captured from the Mayo Clinic 
Cost Data Warehouse (MCCDW), formerly known as the Olmsted County Healthcare 
Utilization and Cost Database (OCHEUD) (60)]. MCCDW provides inflation-adjusted 
standardized costs as per Medicare reimbursement rates for every service and procedure 
received by patients at Mayo Clinic, including inpatient and outpatient and emergency 
room visits. While the details of the costing method is provided elsewhere (60), briefly, 
MCCDW uses a Medicare cost-to-charge ratio that is established for each calendar year 
to value Medicare Part A items (e.g., room and board), while Medicare Part B 
reimbursement rates are applied for costing items in the Part B list (e.g., physician 
consultation, diagnostic and therapeutic procedures).  For each patient in this study, 
standardized costs were extracted from the date of surgery through 30 days post-surgery 
and inflated to 2012 values. 
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Since the type of procedure (robotic-assisted versus open) was not randomly assigned in 
this retrospective cohort, we used propensity score (PS) matching to obtain matched 
cohorts with potentially balanced differences in measured baseline patient 
characteristics . A PS was defined as the estimated probability of a patient having a 
robotic-assisted procedure given a set of measured baseline patient covariates, and was 
derived from a multivariable logistic regression model that included the following 9 
covariates: age (and age2), BMI, Charlson index, ASA, prior abdominal surgery (yes vs. 
no), parity, prior cesarean section (yes vs. no), preoperative histology (endometrioid vs. 
non-endometrioid vs. complex hyperplasia), and preoperative FIGO grade. Prior to 
fitting the logistic model, missing values were imputed for patients with missing BMI or 
Charlson index using the overall median for each covariate. Patients who underwent a 
robotic-assisted procedure were matched 1:1 to patients who underwent an open 
procedure using a greedy matching algorithm that matched on a) the logit of the PS 
within 0.2 of the standard deviation of the logit, b) surgery date within 180 days in the 
same calendar year, and c) histology. For each robotic-assisted case, a patient with an 
open procedure was randomly selected from the potential pool of patients with an open 
procedure defined by the matching calipers. Standardized differences for each covariate 
were calculated to assess the balance between the matched groups. Comparisons were 
made between the two procedures groups (full cohort of open vs. robotic-assisted; 
matched cohort of open vs. robotic-assisted) using the chi-square test or Fisher’s exact 
test for categorical variables and the Wilcoxon rank sum test for all other variables. All 
calculated p-values were two-sided and p-values less than 0.05 were considered 
statistically significant.  Statistical analysis was performed using the SAS software 
package, version 9.3 (SAS Institute, Inc.; Cary, NC). 
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Results: 
During the study period, 1,118 consecutive EC patients (with non-stage IV 
disease) had primary surgical treatment at our institution. Among these, 727 patients 
had surgical staging: 92 (13%) had a combination of vaginal and laparoscopic surgery, 
251 (35%) had robotic-assisted surgery, and 384 (53%) had open staging (Figure 5 and 
6).  The proportion of robotic-assisted procedures per calendar year increased over the 
study period, while the proportion of open surgeries declined dramatically (p<0.001). 
Specifically, the proportion of robotic-assisted procedures increased from 4% in 2007 to 
56% in 2012, whereas the proportion of open procedures decreased from 79% in 2007 
to 34% in 2012 (Figure 6).  
 
Figure 6 : Changes in surgical approaches over the time 
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The results hereafter focus on the patients with either surgical staging via 
robotic-assisted or open surgery (251 robotic and 384 open). The left-hand side of Table 
3 reports the general demographic and preoperative characteristics of patients.  
In comparison to open abdominal procedures, robotic-assisted surgery correlated 
with lower postoperative complications rate within 30 days, lower peri-operative 
transfusion rate, lower readmission rate within 30 days of the surgery, shorter median 
length of hospital stay, but longer operating time. . Patients in the robotic-assisted 
surgery cohort had significantly lower median costs from surgery to discharge ($18,517 
vs. 19,737; p=0.024), than patients treated with open surgery. Consistent with the 
shorter operating time for the open cohort, costs of the operative room and anesthesia 
were significantly lower in the open cohort. Likewise, consistent with the shorter length 
of hospital stay in the robotic-assisted cohort, the total “room and board” costs for the 
initial hospitalization were significantly lower in the robotic-assisted cohort. Surgery-
related outcomes and costs are summarized in Table 4.  
Of note, we observed that one of the factors impacting costs in the robotic group 
was conversion from robotic-assisted to open surgery. Overall 26 (10%) conversions 
occurred. The reasons for conversion included need to complete comprehensive surgical 
staging for the presence of high-risk disease and/or positive lymph nodes at frozen 
section analysis (n=22), bleeding (n=2), adhesions (n=1) and technical issues (n=1). The 
median cost of the initial hospitalization was $5,951 higher for robotic assisted patients 
who had a conversion compared to robotic-assisted patients who did not have a 
conversion; the median total cost from surgery to 30 days post-surgery was $7,579 
higher between these two groups. Table 5 reports outcomes based on all 251 robotic-
assisted cases, separately for the converted and not converted.  
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PS-Matched analysis comparing robotic-assisted and open staging surgery 
The unadjusted results described above are based on two cohorts that differ in 
terms of clinical variables. In fact, cases treated with open surgery had significantly 
higher risk features (like grade 3, non-endometrioid histology – Table 3) in comparison 
to patients included in the robotic-assisted cohort. For this reason, in order to perform a 
more appropriate comparison of similar patients, we used PS methodology to obtain 
matched cohorts with potentially balanced differences in measured baseline patient 
characteristics. A total of 129 propensity-matched pairs (258 patients) undergoing 
staging were identified.  By doing this, we excluded mainly patients in the open group 
who had high-risk characteristics (grade 3, non-endometrioid histology), with associated 
higher morbidity and costs, and patients in the robotic-assisted group with low risk 
characteristics and associated lower morbidity and costs (data not shown).  The right-
hand side of Table 3 summarizes baseline characteristics within the PS-matched cohort 
and presents the standardized difference for each covariate within the full cohort and the 
PS-matched cohort. The decrease in the total standardized difference for the full cohort 
of patients with open and robotic-assisted procedures compared with the matched cohort 
(2.791 to 0.582, respectively) demonstrates a substantial reduction (79%) in bias due to 
measured covariates with PS-matching methodology. The similar distribution of PS 
values between the two matched groups is displayed in Figure 7. 
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 Figure 7: Distribution of propensity-score values 
 
Surgery-related outcomes and costs compared between the PS-matched groups 
are summarized in Table 6  The proportion of patients with an intraoperative 
complication was statistically similar in the two groups, as was the proportion with a 
postoperative grade 3 or higher complication within 30 days. However, patients with a 
robotic-assisted surgery had a significantly lower postoperative grade 2 or higher 
complication rate (7.0% vs. 20.2%; p=0.007), lower blood transfusion rate (3.1% vs. 
24.0%; p<0.001), longer operating time (median, 4.6 vs. 2.5 hours; p<0.001), and 
shorter length of stay (median, 1 vs. 3 days; p<0.001). Readmission rate was lower after 
robotic than open surgery (5.4% vs. 9.3%); however this difference was not statistically 
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significant (p=0.23) Overall, the median total cost from surgery to 30 days post-surgery 
was similar in the PS-matched groups, (open approach was $58 (difference in medians) 
more costly than robotic staging; p=0.66). Similarly, no significant difference between 
open and robotic-assisted was observed in total costs from admit to discharge 
(difference in medians, $96; p=0.30). Robotic-assisted surgery had significantly higher 
median operating room costs (difference in medians, $2,530; p<0.001), but lower 
median “room and board” costs (difference in medians $2,407); p<0.001) in comparison 
to open surgery.  
Comparison of Early and Late Phases of Robotic-Assisted Surgery 
Robotic-assisted surgery was introduced in 2007 at our institution. Due to the 
initial “implementation phase”, through the study period [2007-2008 (n=10) vs. 2009-
2010 (n=120) vs. 2011-2012 (n=121)] the increasing experience with robotic-assisted 
staging correlated with a decrease of operative time, length of stay, conversions as well 
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Table 3: Summary of the baseline characteristics and the standardized differences 
within the full cohort and the PS-matched pairs cohort. 















Age	  (years),	  mean	  (SD)	   62.9	  (10.0)	   64.1	  (10.7)	   0.114	   	  	   63.2	  (9.9)	   62.1	  (10.7)	   0.105	  
BMI	  (kg/m2),	  mean	  (SD)	   35.0	  (9.2)	   34.2	  (8.9)	   0.094	   	  	   34.7	  (9.5)	   35.3	  (8.4)	   0.067	  
Charlson	  index,	  mean	  (SD)	   3.0	  (1.8)	   3.4	  (2.2)	   0.197	   	  	   3.0	  (1.8)	   3.2	  (2.2)	   0.067	  
ASA	  ≥2,	  N	  (%)	   94	  (37.5%)	   167	  (43.5%)	   0.123	   	  	   52	  (40.3%)	   54	  (41.9%)	   0.032	  
Parity,	  mean	  (SD)	   2.2	  (1.9)	   2.4	  (1.8)	   0.136	   	  	   2.1	  (1.6)	   2.1	  (1.6)	   0.048	  
Prior	  cesarean	  section,	  N	  (%)	   35	  (13.9%)	   30	  (7.8%)	   0.198	   	  	   8	  (6.2%)	   12	  (9.3%)	   0.116	  
Prior	  abdominal	  surgery,	  N	  (%)	   100/244	  (41.0%)	   150/375	  (40.0%)	   0.016	   	  	   52/129	  (40.3%)	   55/128	  (43.0%)	   0.047	  
Preoperative	  histology,	  N	  (%)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	  	  Non-­‐endometrioid	   37	  (14.7%)	   107	  (27.9%)	   0.325	   	  	   25	  (19.4%)	   25	  (19.4%)	   0	  
	  	  	  Endometrioid	   200	  (79.7%)	   238	  (62.0%)	   0.397	   	  	   100	  (77.5%)	   100	  (77.5%)	   0	  
	  	  	  Complex	  hyperplasia	   8	  (3.2%)	   10	  (2.6%)	   0.035	   	  	   2	  (1.6%)	   2	  (1.6%)	   0	  
	  	  	  No	  endometrial	  sampling	   6	  (2.4%)	   29	  (7.6%)	   0.239	   	  	   2	  (1.6%)	   2	  (1.6%)	   0	  
Preoperative	  grade,	  N	  (%)	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	  	  1	   129	  (51.4%)	   133	  (34.6%)	   0.343	   	  	   56	  (43.4%)	   59	  (45.7%)	   0.047	  
	  	  	  2	   61	  (24.3%)	   87	  (22.7%)	   0.039	   	  	   34	  (26.4%)	   32	  (24.8%)	   0.036	  
	  	  	  3	   55	  (21.9%)	   135	  (35.2%)	   0.296	   	  	   37	  (28.7%)	   36	  (27.9%)	   0.017	  















† The standardized differences based on the comparisons using the PS-matched pairs are all below the recommended threshold of 0.10, except for two 
at 0.105 and 0.116.  The percent reduction in the overall standardized differences was 79.1%. 
	   38	  
Table 4: Surgery-related outcomes and costs of open and robotic-assisted surgical staging 
Outcome Open  (N=384) Robotic-Assisted (N=251) p value‡ 
Intraoperative complication, N (%) 5 (1.3%) 1 (0.4%) 0.41 
Postoperative complication grade 2+, N (%) † 92 (24.0%) 16 (6.4%) <0.001 
Postoperative complication grade 3+, N (%) † 37 (9.6%) 8 (3.2%) 0.002 
Blood transfusion, N (%) 87 (22.7%) 11 (4.4%) <0.001 
Operating time (hours), Median (IQR) 2.8 (2.3, 3.6)  4.5 (3.6, 5.4)  <0.001 
Length of stay (days), Median (IQR) 4 (3, 5)  1 (1,2)  <0.001 
Readmitted within 30 days, N (%) 49 (12.8%) 9 (3.6%) <0.001 
        
Costs *       
Overall, surgery to 30 days post-surgery     0.024 
        Mean (SD) 23075 (12353) 20393 (6638)   
        Median (IQR) 19737 (16568, 25275) 18517 (16572, 22575)   
Initial hospitalization, surgery to discharge     0.21 
   Total       
        Mean (SD) 20217 (6003) 19333 (4752)   
        Median (IQR) 18949 (16196, 22263) 18203 (16330, 21248)   
   Index procedure     0.19 
        Mean (SD) 2248 (567) 2122 (325)   
        Median (IQR) 2127 (2061, 2269) 2128 (2075, 2176)   
   Anesthesia  (index procedure)     <0.001 
        Mean (SD) 679 (161) 860 (165)   
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Outcome Open  (N=384) Robotic-Assisted (N=251) p value‡ 
        Median (IQR) 686 (585, 765) 854 (757, 960)   
   Operating room (index procedure)     <0.001 
        Mean (SD) 4461 (763) 7296 (1195)   
        Median (IQR) 4393 (3929, 4807) 7014 (6391, 8137)   
   Room and board     <0.001 
        Mean (SD) 4968 (2845) 1942 (1891)   
        Median (IQR) 4180 (3284, 5654) 1191 (1045, 2334)   
Discharge to 30 days post-surgery     0.68 
         Mean (SD) 2859 (10018) 1060 (3922)   
        Median (IQR) 0 (0, 358) 0 (0, 318)   
Abbreviation: ICU, intensive care unit; IQR, interquartile range; Room and board costs included costs of regular room as well as 
any ICU stay.  
† Postoperative complications were within 30 days of the surgery and were graded per the Accordion classification as part of the 
data collection. [76]  
‡ Comparisons based on the chi-square test or Fisher’s exact test for categorical variables and the Wilcoxon rank sum test for all 
other variables. 
* Costs were set based on the Medicare cost-to-charge ratio for each calendar year and inflated to 2012 US dollars. 
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Table 5: Surgery-related outcomes and costs of patients experiencing conversion from robotic-
assisted to open surgery 
 
Outcome 
Robotic-Assisted,   





Intraoperative complication, N (%) 1 (0.4%) 0 1.00 
Postoperative complication grade 2+, N 
(%) †  
11 (4.9%) 5 (19.2%) 0.016 
Postoperative complication grade 3+, N 
(%) † 
6 (2.7%) 2 (7.7%) 0.20 
Blood transfusion, N (%) 7 (3.1%) 4 (15.4%) 0.018 
Operating time (hours), Median (IQR) 4.4 (3.5, 5.2)  5.6 (4.6, 6.6)  <0.001 
Length of stay (days), Median (IQR)  1 (1, 2)  3 (3, 4) <0.001 
Readmitted within 30 days, N (%) 7 (3.1%) 2 (7.7%) 0.24 
        
Cost *       
Overall, surgery to 30 days post-surgery     <0.001 
        Mean (SD) 19468 (5700) 28398 (8671)   
        Median (IQR) 18126 (16330, 21060) 25705 (23233, 29297)   
Initial hospitalization, surgery to 
discharge 
    <0.001 
   Total       
        Mean (SD) 18620 (3978) 25499 (6317)   
        Median (IQR) 17718 (16036, 20232) 23669 (22159, 27434)   
   Index procedure     0.045 
        Mean (SD) 2103 (298) 2290 (477)   
        Median (IQR) 2124 (2088, 2176) 2201 (2074, 2502)   
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Outcome 
Robotic-Assisted,   





   Anesthesia (index procedure)     <0.001 
        Mean (SD) 849 (164) 955 (143)   
        Median (IQR) 845 (751, 942) 976 (875, 1027)   
   Operating room (index procedure)     0.21 
        Mean (SD) 7270 (1179) 7526 (1332)   
        Median (IQR) 6949 (6391, 8115) 7380 (6813, 8189)   
   Room and board     <0.001 
        Mean (SD) 1643 (1473) 4525 (2928)   
        Median (IQR) 1167 (1008, 2244) 3567 (3236, 4765)   
Discharge to 30 days post-surgery     0.002 
         Mean (SD) 848 (3274) 2900 (7338)   
        Median (IQR) 0 (0, 235) 348 (0, 2187)   
Abbreviation: ICU, intensive care unit; IQR, interquartile range; Room and board costs included costs of regular room as well as 
any ICU stay.  
† Postoperative complications were within 30 days of the surgery and were graded per the Accordion classification as part of the 
data collection. [76]  
‡ Comparisons based on the Fisher’s exact test for categorical variables and the Wilcoxon rank sum test for all other variables. 
* Costs were set based on the Medicare cost-to-charge ratio for each calendar year and inflated to 2012 US dollars. 
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Table 6:  Comparison of surgery-related outcomes and costs based on the 129 propensity score-
matched pairs of open and robotic-assisted cases. 
Outcome Open (N=129) Robotic-Assisted (N=129) p value‡ 
Intraoperative complication, N (%)  1 (0.8%) 1 (0.8%) 1.00 
Postoperative complication grade 2+, N (%) †  26 (20.2%) 9 (7.0%) 0.002 
Postoperative complication grade 3+, N (%) †             9 (7.0%)            5 (3.9%) 0.27 
Blood transfusion, N (%) 31 (24.0%) 4 (3.1%) <0.001 
Operating time (hours), Median IQR) 2.5 (1.9, 3.2) 4.6 (3.9, 5.3)  <0.001 
Length of stay (days), Median (IQR) 3 (2, 4) 1 (1, 2)  <0.001 
Readmitted within 30 days, N (%) 12 (9.3%) 7 (5.4%) 0.23 
        
Costs *       
Overall, surgery to 30 days post-surgery   0.66 
        Mean (SD) 21856 (11463) 20892 (7472)   
        Median (IQR) 18811 (16248, 23039) 18753 (16909, 22575)   
Initial hospitalization, surgery to discharge     0.30 
   Total       
        Mean (SD) 19430 (5648) 19509 (4967)   
        Median (IQR) 18317 (15500, 21345) 18413 (16786, 20917)   
   Index procedure     0.99 
        Mean (SD) 2228 (327) 2116 (335)   
        Median (IQR) 2126 (2075, 2224) 2128 (2097, 2180)   
   Anesthesia (index procedure)     <0.001 
        Mean (SD) 722 (127) 849 (171)   
	   43	  
Outcome Open (N=129) Robotic-Assisted (N=129) p value‡ 
        Median (IQR) 710 (650, 772) 859 (751, 960)   
   Operating room (index procedure)     <0.001 
        Mean (SD) 4615 (842) 7271 (1070)   
        Median (IQR) 4419 (3982, 5059) 6949 (6508, 8115)   
   Room and board     <0.001 
        Mean (SD) 4390 (2569) 1983 (2015)   
        Median (IQR) 3574 (2422, 4843) 1167 (1008, 2334)   
Discharge to 30 days post-surgery     0.79 
         Mean (SD) 2426 (8768) 1383 (4953)   
        Median (IQR) 0 (0, 269) 0 (0, 318)   
Abbreviation: ICU, intensive care unit; IQR, interquartile range; Room and board costs included costs of regular room as well as 
any ICU stay.  
† Postoperative complications were within 30 days of the surgery and were graded per the Accordion classification as part of the 
data collection. [76] 
‡ Comparisons based on the chi-square test or Fisher’s exact test for categorical variables and the Wilcoxon rank sum test for all 
other variables. 
* Costs were set based on the Medicare cost-to-charge ratio for each calendar year and inflated to 2012 US dollars. 
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Table 7:  Comparison across time periods of baseline characteristics and surgery-related outcomes 
















Age (years), mean (SD) 63.2 (8.3) 62.1 (10.5) 63.6 (9.5) 0.48 
BMI (kg/m2), mean (SD) 32.8 (6.2) 35.6 (10.2) 34.6 (8.3) 0.54 
Charlson index, mean (SD) 3.0 (1.3) 3.0 (1.7) 3.0 (1.9) 0.99 
ASA ≥2, n (%) 5 (50.0%) 42 (35.0%) 47 (38.8%) 0.58 
Parity, mean (SD) 1.7 (1.3) 2.2 (2.2) 2.2 (1.7) 0.71 
Prior cesarean section, n (%) 0 (0.0%) 17 (14.2%) 18 (14.9%) 0.42 
Prior abdominal surgery, n 
(%) 
4 (40.0%) 54 (45.0%) 42 (34.7%) 0.26 
Preoperative histology, n (%)       0.74 
     Non-endometrioid 3 (30.0%) 15 (12.5%) 19 (15.7%)   
     Endometrioid 7 (70.0%) 99 (82.5%) 94 (77.7%)   
     Complex hyperplasia 0 (0.0%) 3 (2.5%) 5 (4.1%)   
     No endometrial sampling 0 (0.0%) 3 (2.5%) 3 (2.5%)   
Preoperative grade, n (%)       0.83 
     1 4 (40.0%) 60 (50.0%) 65 (53.7%)   
















     2 2 (20.0%) 32 (26.7%) 27 (22.3%)   
     3 4 (40.0%) 25 (20.8%) 26 (21.5%)   
     No endometrial sampling 0 (0.0%) 3 (2.5%) 3 (2.5%)   
          
Intraoperative complication, N 
(%)  
0 (0.0%) 1 (0.8%) 0 (0.0%) 0.52 
Postoperative complication gr
ade 2+, N (%) †  
2 (20.0%) 9 (7.5%) 5 (4.1%) 0.11 
Postoperative complication gr
ade 3+, N (%) † 
1 (10.0%) 3 (2.5%) 4 (3.3%) 0.33 
Blood transfusion, N (%) 1 (10.0%) 7 (5.8%) 3 (2.5%) 0.30 
Operating time (hours), 
Median IQR) 
6.1 (5.4, 7.0) 4.4 (3.6, 5.4) 4.3 (3.5, 5.1) 0.002 
Conversion, N (%) 3 (30.0%) 10 (8.3%) 13 (10.7%) 0.11 
Length of stay (days), Median 
(IQR) 
2 (2, 3) 1 (1, 2)  1 (1, 2) 0.002 










Abbreviation: ICU, intensive care unit; IQR, interquartile range; Room and board costs included costs of 
regular room as well as any ICU stay.  
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† Postoperative complications were within 30 days of the surgery and were graded per the Accordion 
classification as part of the data collection. [18] 
‡ Comparisons based on the chi-square test or Fisher’s exact test for categorical variables, the F-test from 
a one-way ANOVA model for age, BMI, Charlson index, and parity, and the Kruskal-Wallis test for 
operating time and length of stay. 
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Conclusions: 
The present study evaluated how the introduction of robotic-assisted surgery 
influenced morbidity and costs related to EC staging, thus demonstrating a number of 
noteworthy findings. First, our results demonstrated that the implementation of robotic- 
assisted technology has reduced the rate of open abdominal staging for EC patients. 
Second, we observed that patients with EC who are surgically staged using robotic-
assisted surgery have significantly better perioperative outcomes (postoperative 
complications, transfusions, length of stay, readmissions) and lower overall costs when 
compared to patients staged with open surgery. When taking into account the 
differences between the two cohorts (patients who had open surgery had more 
aggressive cancers), and considering only a PS-matched population, perioperative 
clinical outcomes were still significantly better in the robotic-assisted population, but 
with similar total costs. Third, we observed that conversion from robotic-assisted to 
open surgery increases morbidity and costs, thus suggesting the need (when possible) to 
maximize our attempts to complete surgery with a minimally invasive approach. Fourth, 
our data suggested that increased experience in robotic-assisted surgery correlates with 
improved surgical outcomes, with potential improved patients’ turnover and costs’ 
saving.  
Although robotic-assisted surgery has been harshly criticized to be costly and 
unnecessary, robotic-assisted surgery is increasingly being used in the setting of both 
benign and malignant diseases (77,78). Interestingly, as of December 31, 2014, 2,233 da 
Vinci robotic systems have been installed in the US, with more than 1,200 gynecologic 
surgeons who have been trained to use this device (77,78). Owing these features, 
thorough investigation of the economic impact of robotic-assisted surgery on healthcare 
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system is paramount. In fact, costs of acquisition of the surgical system ($0.6M-$2.5M), 
maintenance fees ($100,000-$170,000, annually) and instruments and accessories 
represent the main barrier against its universal adoption (77,78).  
As demonstrated by the present paper and others, the implementation of robotic-
assisted surgery is associated with a reduction of open abdominal procedure rates 
(63,69,77). Lau et al. reported that the introduction of robotic-assisted surgery increases 
the number of patients undergoing staging surgery via a minimally invasive approach, 
thus improving patients outcomes and reducing the overall hospital costs (63). 
Similarly, Leitao et al., in a cost modeling based on a theoretical scenario characterized 
by the implementation of robotic-assisted surgery into a clinical setting (in which the 
rate of laparoscopic procedures is stable over the years), observed that the introduction 
of robotic-assisted surgery decreases costs, reducing open abdominal procedure rates 
(69). However, two criticisms of this model are: (a) these results arise from a 
hypothetical model; (b) the model is based on the results of a comparison in which 
patients had planned robotic-assisted and open abdominal procedures on the basis of 
constitutional and disease variables; hence, we can expect (like in our first unmatched 
comparison in Table 1) that the two groups are not fully comparable. Our investigation 
overcomes these two concerns. In fact, our study is the first demonstrating the beneficial 
effect of the introduction of robotic-assisted surgery into a preexisting clinical setting, 
utilizing the PS analysis. This analysis enabled us to balance observed covariates 
between patients in the two surgical groups, and thereby obtain potentially less biased 
comparisons of outcome measures between the two approaches. As supported by the 
findings of other authors, we observed that robotic-assisted surgery increases costs 
related to the surgical procedure itself, especially due to the longer operative time 
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needed to perform staging when compared to open surgery; but, costs related to the 
postoperative period are decreased due to a shorter length of hospital stay and a lower 
rate of complications. Moreover, the introduction of robotic-assisted surgery may 
improve patients’ turnover. At academic medical centers such as ours, limited bed 
capacity is an ongoing concern. There are concerted efforts to reduce length of hospital 
stay based on clinical guidelines and benchmarked comparative length of stay data, and 
bed control staff monitor bed availability and facilitate patient flow. Our unmatched 
data demonstrated that robotic-assisted surgery has a lower length of stay compared to 
open surgery (1 vs. 4 days), and this reduction has helped facilitate hospital patient flow 
and increased patient access to our hospital gynecologic surgery unit. Based on the data 
of our institution, over the study period, robotic-assisted surgery may potentially have 
saved 750 bed days, thus allowing for care of additional patients without increase in 
facility or staff. In fact, considering patients undergoing endometrial cancer surgical 
staging via robotic-assisted approach versus an open approach, over the six-year study 
period, 250 to 500 additional patients could have been served within the surgical 
hospital unit by utilizing robotic-assisted surgery.   
While some previous health economic publications have focused on the cost of 
care from admission to discharge, we expanded this time horizon to include the 30-day 
readmission period in addition to the initial admit to discharge period. We included the 
readmission time period as hospitals are increasing focusing on readmission rates and 
their associated cost and especially given the focus within the Affordable Care Act (79). 
The Hospital Readmissions Reductions Program, which started on October 1, 2012 (FY 
’13), cut up to 1% of Medicare inpatient payments for hospitals with excess 
readmissions for patients with pneumonia, heart failure, and acute myocardial 
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infarctions. This penalty increased to 2% in FY ’14, and starting on October 1, 2015 
(FY ’15), the maximum penalty for excess readmissions is 3%, which is the highest 
allowable based on ACA regulations. Added to the list of clinical indications included 
in the Hospital Readmissions Reductions Program in FY ’15 are chronic obstructive 
pulmonary disease and knee and hip arthroplasty. Although surgical interventions are 
not on the list of indications included in the Hospital Readmissions Reductions 
Programs, readmissions for any cause impact hospital throughput, capacity, and 
financials, and this is true even at our institution. Data from our unmatched group 
indicates that robotic-assisted surgery had a lower readmission rate (3.6% vs. 12.8%) 
compared to open surgery. On average, readmissions cost to our institution for 
endometrial cancer patients is $ 13,263.  To calculate a cost savings due to the reduction 
in readmission attributable to robotic-assisted surgery, we utilized the unmatched data 
as it demonstrates the true change in practice patterns. Over the time period of our 
analysis, robotic-assisted surgery saved the institution more than $ 3,000,000.00 (0.92 X 
251 robotic patients X $13,263  (average cost of readmission)) due to lower readmission 
rates. Similarly other authors have shown that, compared to open surgery, robotic-
assisted surgery has the ability to significantly lower readmission rates and in turn, save 
costs (63,67,69,70), which are crucial elements in today’s healthcare environment. 
 Another interesting point of the present investigation, which was not analyzed 
by previously published studies on this issue, is represented by the evaluation of the 
impact of the initial “implementation phase” on the cost-effectiveness of robotic-
assisted surgery. Interestingly, we observed that increasing expertise in robotic-assisted 
surgery improves surgery-related outcomes, including a significant decrease of 
readmissions. Although it is not possible provide a fair comparison on costs between 
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different time periods (since costs are established each year based on the Medicare cost-
to-charge ratio for that calendar year), we can speculate that the reduction of operative 
time, length of hospital stay and complication rates potentially play a role in minimizing 
the burden of the healthcare 
Another point deserving attention is the exclusion of patients undergoing 
laparoscopic staging. However, as it is evident from figures 1 and 2, historically, 
laparoscopy had a limited role in our department. Only the advent of robotic surgery 
allowed having a clear shift from open to minimally invasive surgery in endometrial 
cancer at our Institution, like in the rest of the US and Canada (63, 69). Also, it is 
generally suggested that robotic-assisted surgery increased costs in comparison to 
conventional laparoscopic surgery (67-69). However, these costs only reflect the 
hospital standpoint; while previously published investigations suggested that the main 
advantages of the robotic-assisted surgery are based on the reduction of costs from a 
societal prospective (i.e. the possibility for more women to have access to minimally 
invasive surgery), thus suggesting the need of further studies comparing robotic and 
laparoscopic staging procedures.  
The main weaknesses of the present study include the inherent biases of a single 
institution, non-randomized study design. Additionally, we did not consider 
amortization costs, which obviously may influence our results, in institutions lacking 
robotic system. However, as aforementioned many institutions already have robotic 
systems in the US. Therefore our results clearly reflect a commonly observed scenario.  
Strengths of the present study include the large sample size, and the use of a PS 
analysis, which reduces the potential bias of measured covariates driving the choice of 
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surgical approach. Moreover, other novelties of the present investigation include the 
evaluation of the impact of the initial “implementation phase” and conversions on costs 
of EC patients surgically staged via the robotic-assisted approach. 
In conclusion, the present study evaluated the impact of the implementation of 
robotic-assisted technology on morbidity and costs of surgically staged EC. Our 
findings demonstrated that the implementation of robotic-assisted surgery, in a setting 
of surgically staged EC, allows more patients to be treated with minimally invasive 
surgery, thus decreasing morbidity and overall costs. The observed decrease in length of 
hospital stay and readmission introduced with robotic-assisted surgery promotes a more 
rapid turnover of patients, thus improving patient access, in comparison with open 
surgery. Increasing experience with robotic-assisted platform and attempts to decrease 
conversions significantly improve patient outcomes and potentially decrease costs. 
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